Group 1 - Baiyang Pharmaceutical has experienced a decline for four consecutive trading days, with a cumulative drop of -3.93% [1] - The company, established in 2005, focuses on the development, manufacturing, and commercialization of medical innovations, aiming to optimize healthcare through technological advancements [1] - ICBC Credit Suisse Asset Management has two funds among the top ten shareholders of Baiyang Pharmaceutical, with one fund reducing its holdings and the other entering the position in the second quarter of this year [1] Group 2 - ICBC Credit Suisse Fund's "ICBC Frontier Medical Stock A" has a year-to-date return of 33.52%, ranking 190 out of 976 in its category, while "ICBC Healthcare Stock" has a return of 32.51%, ranking 206 out of 976 [2] - The fund managers for these funds are Zhao Bei and Ding Yang, with Zhao having over ten years of experience in the industry and currently managing multiple funds [5][6] - Ding Yang, who joined ICBC Credit Suisse in December 2017, has been managing the healthcare industry stock fund since May 2023 [7]
百洋医药连跌4天，工银瑞信基金旗下2只基金位列前十大股东